SG11201901494UA - Acid-alpha glucosidase variants and uses thereof - Google Patents
Acid-alpha glucosidase variants and uses thereofInfo
- Publication number
- SG11201901494UA SG11201901494UA SG11201901494UA SG11201901494UA SG11201901494UA SG 11201901494U A SG11201901494U A SG 11201901494UA SG 11201901494U A SG11201901494U A SG 11201901494UA SG 11201901494U A SG11201901494U A SG 11201901494UA SG 11201901494U A SG11201901494U A SG 11201901494UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rue
- paris
- evry
- september
- Prior art date
Links
- 102000004366 Glucosidases Human genes 0.000 title abstract 3
- 108010056771 Glucosidases Proteins 0.000 title abstract 3
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306150.0A EP3293260A1 (en) | 2016-09-12 | 2016-09-12 | Acid-alpha glucosidase variants and uses thereof |
EP16306187 | 2016-09-16 | ||
PCT/EP2017/072944 WO2018046774A1 (en) | 2016-09-12 | 2017-09-12 | Acid-alpha glucosidase variants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901494UA true SG11201901494UA (en) | 2019-03-28 |
Family
ID=59887252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901494UA SG11201901494UA (en) | 2016-09-12 | 2017-09-12 | Acid-alpha glucosidase variants and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (2) | US11339406B2 (ja) |
EP (1) | EP3510149A1 (ja) |
JP (2) | JP7245155B2 (ja) |
KR (2) | KR20240001721A (ja) |
CN (2) | CN110050063B (ja) |
AU (2) | AU2017322376B2 (ja) |
BR (1) | BR112019004785A2 (ja) |
CA (1) | CA3035868A1 (ja) |
CL (1) | CL2019000609A1 (ja) |
CO (1) | CO2019002252A2 (ja) |
IL (2) | IL299325A (ja) |
MX (1) | MX2019002842A (ja) |
PE (1) | PE20191203A1 (ja) |
PH (1) | PH12019500408A1 (ja) |
SG (1) | SG11201901494UA (ja) |
WO (1) | WO2018046774A1 (ja) |
ZA (1) | ZA201902141B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
EP3635009A1 (en) | 2017-06-07 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
CN113747926A (zh) | 2019-04-08 | 2021-12-03 | 吉尼松公司 | 用于肌肉表达的杂合启动子 |
MX2021013365A (es) * | 2019-04-30 | 2022-01-26 | Univ Pennsylvania | Composiciones utiles para el tratamiento de la enfermedad de pompe. |
JP2022540632A (ja) | 2019-07-09 | 2022-09-16 | ジェネトン | 糖原病(gsd)の処置 |
CA3145112A1 (en) * | 2019-07-26 | 2021-02-04 | Chunping Qiao | Engineered nucleic acid regulatory element and methods of uses thereof |
JP2022553550A (ja) | 2019-10-22 | 2022-12-23 | ジェネトン | キメラポリペプチド及びその使用 |
WO2021078834A1 (en) | 2019-10-22 | 2021-04-29 | Genethon | Chimeric acid-alpha glucosidase polypeptides and uses thereof |
CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
US20230365955A1 (en) | 2020-10-09 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
CN117897492A (zh) | 2021-08-04 | 2024-04-16 | 吉尼松公司 | 用于肌肉和cns中的基因表达的杂合启动子 |
WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
WO2023150620A1 (en) * | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Crispr-mediated transgene insertion in neonatal cells |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858425B1 (en) | 1998-12-04 | 2005-02-22 | Genzyme Corporation | Human acid alpha glucosidase gene and bovine alpha-S1 casein gene sequences |
DK1137762T3 (da) | 1998-12-07 | 2009-02-02 | Genzyme Corp | Behandling af Pompes sygdom |
US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
EP1587923B1 (en) | 2003-01-22 | 2011-08-24 | Duke University | Improved constructs for expressing lysosomal polypeptides |
CN1922313B (zh) | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
ES2647477T3 (es) | 2004-06-01 | 2017-12-21 | Genzyme Corporation | Composiciones y métodos para prevenir la agregación del vector AAV |
WO2010005565A2 (en) | 2008-07-08 | 2010-01-14 | Duke University | Method of treating glycogen storage disease |
KR101618767B1 (ko) * | 2008-09-02 | 2016-05-09 | 한국생명공학연구원 | 외래단백질을 고효율로 생산하는 리더서열 |
EP2344524B1 (en) * | 2008-10-02 | 2019-12-04 | Unitargeting Research As | Kit for the optimisation of protein synthesis/secretion |
US9598682B2 (en) | 2009-09-29 | 2017-03-21 | Vib Vzw | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
JP6151183B2 (ja) | 2010-09-29 | 2017-06-21 | オキシレイン ユーケー リミテッド | マンノース−1−ホスホ−6−マンノース結合からキャップを外すことおよびリン酸化n−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法 |
WO2012085622A1 (en) | 2010-12-22 | 2012-06-28 | Fondazione Telethon | Therapeutic strategies to treat cns pathology in mucopolysaccharidoses |
EP2471929A1 (en) * | 2010-12-29 | 2012-07-04 | Algenics | Production of high mannose glycosylated proteins stored in the plastid of microalgae |
PE20140617A1 (es) | 2011-04-22 | 2014-05-28 | Genzyme Corp | Alfa glucosidasa acida modificada con procesamiento acelerado |
WO2013013017A2 (en) | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
MX2014015985A (es) | 2012-06-19 | 2015-07-21 | Univ Florida | Composiciones y metodos para tratar enfermedades. |
CA2877223C (en) | 2012-08-06 | 2019-08-27 | Brainstorm Cell Therapeutics Ltd. | Methods of generating mesenchymal stem cells which secrete neurotrophic factors |
AU2014218854B2 (en) * | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
KR102380265B1 (ko) | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
AU2015219339B2 (en) | 2014-02-19 | 2020-03-05 | Bioasis Technologies Inc. | P97-IDS fusion proteins |
CA2942451A1 (en) | 2014-04-25 | 2015-10-29 | Genethon | Treatment of hyperbilirubinemia |
WO2015192092A1 (en) | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
US10781459B2 (en) | 2014-06-20 | 2020-09-22 | University Of Florida Research Foundation, Incorporated | Methods of packaging multiple adeno-associated virus vectors |
WO2016065319A1 (en) | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
-
2017
- 2017-09-12 PE PE2019000513A patent/PE20191203A1/es unknown
- 2017-09-12 MX MX2019002842A patent/MX2019002842A/es unknown
- 2017-09-12 SG SG11201901494UA patent/SG11201901494UA/en unknown
- 2017-09-12 KR KR1020237043894A patent/KR20240001721A/ko active Search and Examination
- 2017-09-12 CA CA3035868A patent/CA3035868A1/en active Pending
- 2017-09-12 IL IL299325A patent/IL299325A/en unknown
- 2017-09-12 WO PCT/EP2017/072944 patent/WO2018046774A1/en unknown
- 2017-09-12 CN CN201780055024.9A patent/CN110050063B/zh active Active
- 2017-09-12 BR BR112019004785A patent/BR112019004785A2/pt unknown
- 2017-09-12 CN CN202311396633.4A patent/CN117384890A/zh active Pending
- 2017-09-12 EP EP17768081.6A patent/EP3510149A1/en active Pending
- 2017-09-12 US US16/332,379 patent/US11339406B2/en active Active
- 2017-09-12 JP JP2019513378A patent/JP7245155B2/ja active Active
- 2017-09-12 AU AU2017322376A patent/AU2017322376B2/en active Active
- 2017-09-12 KR KR1020197010340A patent/KR102617502B1/ko active IP Right Grant
-
2019
- 2019-02-26 PH PH12019500408A patent/PH12019500408A1/en unknown
- 2019-02-27 IL IL265084A patent/IL265084B2/en unknown
- 2019-03-11 CL CL2019000609A patent/CL2019000609A1/es unknown
- 2019-03-12 CO CONC2019/0002252A patent/CO2019002252A2/es unknown
- 2019-04-05 ZA ZA2019/02141A patent/ZA201902141B/en unknown
-
2022
- 2022-04-25 US US17/727,990 patent/US20220275396A1/en active Pending
-
2023
- 2023-03-10 JP JP2023037619A patent/JP2023072007A/ja active Pending
- 2023-11-03 AU AU2023258449A patent/AU2023258449A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190390225A1 (en) | 2019-12-26 |
CL2019000609A1 (es) | 2019-07-05 |
IL265084B1 (en) | 2023-01-01 |
JP2019533990A (ja) | 2019-11-28 |
US11339406B2 (en) | 2022-05-24 |
KR20240001721A (ko) | 2024-01-03 |
MX2019002842A (es) | 2019-08-29 |
US20220275396A1 (en) | 2022-09-01 |
PE20191203A1 (es) | 2019-09-10 |
BR112019004785A2 (pt) | 2019-06-04 |
RU2019110773A3 (ja) | 2020-11-25 |
ZA201902141B (en) | 2024-03-27 |
CN110050063B (zh) | 2023-11-03 |
CA3035868A1 (en) | 2018-03-15 |
JP2023072007A (ja) | 2023-05-23 |
CN110050063A (zh) | 2019-07-23 |
CN117384890A (zh) | 2024-01-12 |
AU2023258449A1 (en) | 2023-11-23 |
WO2018046774A1 (en) | 2018-03-15 |
PH12019500408A1 (en) | 2020-01-20 |
KR102617502B1 (ko) | 2023-12-26 |
EP3510149A1 (en) | 2019-07-17 |
IL265084A (ja) | 2019-04-30 |
AU2017322376B2 (en) | 2023-08-17 |
JP7245155B2 (ja) | 2023-03-23 |
RU2019110773A (ru) | 2020-10-12 |
KR20190057327A (ko) | 2019-05-28 |
IL299325A (en) | 2023-02-01 |
AU2017322376A1 (en) | 2019-03-28 |
CO2019002252A2 (es) | 2019-05-21 |
IL265084B2 (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201810333UA (en) | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201805898RA (en) | Liquid composition comprising a multistage polymer, its method of preparation and its use | |
SG11201808675VA (en) | Method and kit for the generation of dna libraries for massively parallel sequencing | |
SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11202000494UA (en) | Drug delivery composition |